AB-001
http://dbpedia.org/resource/AB-001 an entity of type: Thing
AB-001 (1-pentyl-3-(1-adamantoyl)indole) is a designer drug that was found as an ingredient in synthetic cannabis smoking blends in Ireland in 2010 and Hungary and Germany in 2011. It is unclear who AB-001 was originally developed by, but it is structurally related to compounds such as AM-1248 and its corresponding 1-(tetrahydropyran-4-ylmethyl) analogue, which are known to be potent cannabinoid agonists with moderate to high selectivity for CB2 over CB1. The first published synthesis and pharmacological evaluation of AB-001 revealed that it acts as a full agonist at CB1 (EC50 = 35 nM) and CB2 receptors (EC50 = 48 nM). However, AB-001 was found to possess only weak cannabimimetic effects in rats at doses up to 30 mg/kg, making it less potent than the carboxamide analogue APICA, which posse
rdf:langString
rdf:langString
AB-001
xsd:integer
33362332
xsd:integer
1082421097
xsd:integer
24
xsd:integer
1345973
xsd:integer
26286891
xsd:integer
31
xsd:integer
1
rdf:langString
Anlage II
rdf:langString
Class B
xsd:integer
1
xsd:integer
1
xsd:integer
57404070
rdf:langString
CCCCCn1ccCC34CC5CCCCC4
xsd:integer
1
rdf:langString
SHWDYCMMUPPWQM-UHFFFAOYSA-N
rdf:langString
H657DIA015
rdf:langString
changed
xsd:integer
460440720
rdf:langString
changed
xsd:integer
200
rdf:langString
AB-001 (1-pentyl-3-(1-adamantoyl)indole) is a designer drug that was found as an ingredient in synthetic cannabis smoking blends in Ireland in 2010 and Hungary and Germany in 2011. It is unclear who AB-001 was originally developed by, but it is structurally related to compounds such as AM-1248 and its corresponding 1-(tetrahydropyran-4-ylmethyl) analogue, which are known to be potent cannabinoid agonists with moderate to high selectivity for CB2 over CB1. The first published synthesis and pharmacological evaluation of AB-001 revealed that it acts as a full agonist at CB1 (EC50 = 35 nM) and CB2 receptors (EC50 = 48 nM). However, AB-001 was found to possess only weak cannabimimetic effects in rats at doses up to 30 mg/kg, making it less potent than the carboxamide analogue APICA, which possesses potent cannabimimetic activity at doses of 3 mg/kg.
rdf:langString
Schedule II
xsd:nonNegativeInteger
5184
xsd:string
1345973-49-0
xsd:string
H657DIA015
xsd:string
57404070